CN110267685B - 靶向adam9的免疫缀合物及其使用方法 - Google Patents

靶向adam9的免疫缀合物及其使用方法 Download PDF

Info

Publication number
CN110267685B
CN110267685B CN201780079982.XA CN201780079982A CN110267685B CN 110267685 B CN110267685 B CN 110267685B CN 201780079982 A CN201780079982 A CN 201780079982A CN 110267685 B CN110267685 B CN 110267685B
Authority
CN
China
Prior art keywords
seq
domain
immunoconjugate
amino acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780079982.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110267685A (zh
Inventor
S·W·希克斯
N·C·尤德
B·巴拉特
E·邦维尼
G·迪德里克
L·S·约翰逊
D·卢
J·A·斯克里布纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macro Genetics Co
Immunogen Inc
Original Assignee
Macro Genetics Co
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macro Genetics Co, Immunogen Inc filed Critical Macro Genetics Co
Publication of CN110267685A publication Critical patent/CN110267685A/zh
Application granted granted Critical
Publication of CN110267685B publication Critical patent/CN110267685B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780079982.XA 2016-12-23 2017-12-21 靶向adam9的免疫缀合物及其使用方法 Active CN110267685B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662438488P 2016-12-23 2016-12-23
US62/438,488 2016-12-23
US201762480201P 2017-03-31 2017-03-31
US62/480,201 2017-03-31
PCT/US2017/067823 WO2018119196A1 (en) 2016-12-23 2017-12-21 Immunoconjugates targeting adam9 and methods of use thereof

Publications (2)

Publication Number Publication Date
CN110267685A CN110267685A (zh) 2019-09-20
CN110267685B true CN110267685B (zh) 2023-06-20

Family

ID=61025051

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780079982.XA Active CN110267685B (zh) 2016-12-23 2017-12-21 靶向adam9的免疫缀合物及其使用方法

Country Status (18)

Country Link
US (1) US20210388102A1 (enExample)
EP (1) EP3558391B1 (enExample)
JP (1) JP7170642B2 (enExample)
CN (1) CN110267685B (enExample)
CY (1) CY1125181T1 (enExample)
DK (1) DK3558391T3 (enExample)
ES (1) ES2912266T3 (enExample)
HR (1) HRP20220550T1 (enExample)
HU (1) HUE058664T2 (enExample)
LT (1) LT3558391T (enExample)
MD (1) MD3558391T2 (enExample)
PL (1) PL3558391T3 (enExample)
PT (1) PT3558391T (enExample)
RS (1) RS63154B1 (enExample)
SI (1) SI3558391T1 (enExample)
SM (1) SMT202200182T1 (enExample)
TW (1) TWI783957B (enExample)
WO (1) WO2018119196A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201934187A (zh) 2018-01-12 2019-09-01 美商免疫遺傳股份有限公司 抗體藥物結合、純化、及調配之方法
JP2021528471A (ja) * 2018-06-26 2021-10-21 イミュノジェン・インコーポレーテッド Ａｄａｍ９を標的とする免疫コンジュゲート、及び、その使用の方法
TW202102270A (zh) 2019-03-21 2021-01-16 美商伊繆諾金公司 製備細胞結合劑-藥物結合物之方法
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
EP3958977B1 (en) 2019-04-26 2023-09-13 ImmunoGen, Inc. Camptothecin derivatives
CN110713983B (zh) * 2019-11-04 2022-06-10 深圳市体内生物医药科技有限公司 一种表达透明质酸酶的免疫细胞及其应用
US20240165256A1 (en) 2021-03-08 2024-05-23 Immunogen, Inc. Methods for increasing efficacy of immunoconjugates targeting adam9 for the treatment of cancer
CN118684724A (zh) 2023-03-22 2024-09-24 映恩生物制药（苏州）有限公司 连接子及其在配体药物偶联物中的应用
AU2024244721A1 (en) 2023-03-24 2025-10-23 Duality Biologics (Shanghai) Co., Ltd. Adam9-targeting humanized antibody and antibody-drug conjugate comprising same and use thereof
WO2025094146A1 (en) 2023-11-02 2025-05-08 Immunogen Switzerland Gmbh Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates
CN120058950A (zh) * 2023-11-28 2025-05-30 昆山新蕴达生物科技有限公司 抗adam9的抗体及其用途
TW202540201A (zh) * 2023-12-14 2025-10-16 大陸商四川科倫博泰生物醫藥股份有限公司 Adam9結合蛋白及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
AU2012250873A1 (en) * 2011-05-02 2013-05-09 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK1252192T3 (da) 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
EP1142910A1 (en) 2000-04-07 2001-10-10 Jürgen Prof. Dr. Frey Inhibitors for the formation of soluble human CD23
US20030091568A1 (en) 2000-04-07 2003-05-15 Jurgen Frey Inhibitors for the formation of soluble human CD23
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
JP2005528082A (ja) 2001-12-18 2005-09-22 モンドバイオテック・ラボラトリーズ・アンスタルト 間質性肺疾患の治療を向上させるためのインターフェロンγ又はパーフェニドンと分子診断薬との新規医薬組成物
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US20040092466A1 (en) 2002-11-11 2004-05-13 Isis Pharmaceuticals Inc. Modulation of ADAM9 expression
DE60336149D1 (de) 2002-08-16 2011-04-07 Immunogen Inc Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
WO2005091823A2 (en) 2004-03-01 2005-10-06 The Regents Of The University Of California The use of lunasin peptide as a transcriptional activator to prevent cancer and related methods for treatment, monitoring and prognosis
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
NZ556561A (en) 2005-02-02 2011-08-26 Macrogenics West Inc Adam-9 modulators
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
CL2007001536A1 (es) 2006-05-30 2008-01-25 Genentech Inc Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
WO2007143752A2 (en) 2006-06-09 2007-12-13 The Regents Of The University Of California Targets in breast cancer for prognosis or therapy
KR101443214B1 (ko) 2007-01-09 2014-09-24 삼성전자주식회사 폐암 환자 또는 폐암 치료를 받은 폐암 환자의 폐암 재발 위험을 진단하기 위한 조성물, 키트 및 마이크로어레이
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
GB2453589A (en) 2007-10-12 2009-04-15 King S College London Protease inhibition
US8101361B2 (en) 2008-03-10 2012-01-24 National Jewish Health Markers for diagnosis of pulmonary inflammation and methods related thereto
JP2011516081A (ja) 2008-04-07 2011-05-26 ザイモジェネティクス， インコーポレイテッド トロンビンアクチベーター組成物ならびにそれを作製および使用する方法
US20090285840A1 (en) * 2008-04-29 2009-11-19 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Methods for treating pathological neovascularization
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
WO2010033279A2 (en) 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
WO2010053539A2 (en) 2008-11-05 2010-05-14 The Texas A&M University System Methods for detecting colorectal diseases and disorders
JP2012510821A (ja) 2008-12-04 2012-05-17 アボット・ラボラトリーズ 二重可変ドメイン免疫グロブリンおよびその使用
SG173152A1 (en) 2009-02-05 2011-08-29 Immunogen Inc Novel benzodiazepine derivatives
MX2011012794A (es) 2009-06-03 2012-05-08 Immunogen Inc Metodos de conjugacion.
WO2011100362A1 (en) 2010-02-11 2011-08-18 University Of Southern California Modified adam disintegrin domain polypeptides and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
KR20190089048A (ko) 2011-02-15 2019-07-29 이뮤노젠 아이엔씨 컨쥬게이트의 제조방법
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013049704A2 (en) 2011-09-28 2013-04-04 Armune Biosciences, Inc. Method and system of particle-phage epitope complex
US20140342946A1 (en) 2011-12-31 2014-11-20 Moni Abraham Kuriakose Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
WO2014108480A1 (en) 2013-01-09 2014-07-17 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method for in vitro detection and monitoring of a disease by measuring disease-associated protease activity in extracellular vesicles
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
EP2985346A4 (en) 2013-04-08 2016-05-25 Mitsubishi Rayon Co MICROARRAY FOR THE EVALUATION OF EYE DISEASES AND EVALUATION METHODS OF EYE DISEASES
WO2014186364A2 (en) 2013-05-13 2014-11-20 Tufts University Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
US20160138113A1 (en) 2013-06-19 2016-05-19 Memorial Sloan-Kettering Cancer Center Methods and compositions for the diagnosis, prognosis and treatment of brain metastasis
US9567641B2 (en) 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US10988531B2 (en) * 2014-09-03 2021-04-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US9381256B2 (en) 2014-09-03 2016-07-05 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US9669102B2 (en) 2014-09-03 2017-06-06 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
JP2018500049A (ja) 2014-11-11 2018-01-11 アムニクス オペレーティング インコーポレイテッド ターゲティングｘｔｅｎコンジュゲート組成物およびそれを作製する方法
SI3313845T1 (sl) 2015-06-29 2021-01-29 Immunogen, Inc. Konjugati spremenjenih protiteles cisteina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10337368A1 (de) * 2003-08-08 2005-03-03 Technische Universität Dresden Verfahren und Mittel zur Diagnose und Behandlung von Pankreastumoren
AU2012250873A1 (en) * 2011-05-02 2013-05-09 Millennium Pharmaceuticals, Inc. Formulation for anti-alpha4beta7 antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Abstract 37: Novel antibody-drug conjugates targeting ADAM9-expressing solid tumors demonstrate potent ADAM9-expressing solid tumors demonstrate potent preclinical activity;Stuart W. Hicks等;《Cancer Res》;20170701;第77卷(第13supplement期);第37页 *
Abstract 38: Target validation, antibody discovery and preclinical data supporting ADAM9 as an antibody-drug conjugate therapeutic target for solid tumors;Juniper A. Scribner等;《Cancer Res》;20170701;第77卷(第13 Supplement期);第38页 *
HDGF 和ADAM9 在非小细胞肺癌中的异常表达及其临床意义;张军等;《中国医科大学学报》;20110330;第40卷(第3期);第280-281页 *
IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models;Sharlene Adams等;《Blood》;20161202;第128卷(第22期);第2832页 *
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates;Hans K. Erickson等;《Bioconjugate Chem》;20091105;第21卷(第1期);第84-92页 *

Also Published As

Publication number Publication date
EP3558391B1 (en) 2022-02-02
EP3558391A1 (en) 2019-10-30
RS63154B1 (sr) 2022-05-31
US20210388102A1 (en) 2021-12-16
PT3558391T (pt) 2022-05-05
MD3558391T2 (ro) 2022-05-31
CY1125181T1 (el) 2024-12-13
TW201822821A (zh) 2018-07-01
WO2018119196A1 (en) 2018-06-28
PL3558391T3 (pl) 2022-05-16
ES2912266T3 (es) 2022-05-25
JP7170642B2 (ja) 2022-11-14
SI3558391T1 (sl) 2022-06-30
CN110267685A (zh) 2019-09-20
SMT202200182T1 (it) 2022-05-12
WO2018119196A8 (en) 2019-06-20
HRP20220550T1 (hr) 2022-06-10
TWI783957B (zh) 2022-11-21
LT3558391T (lt) 2022-07-11
JP2020504607A (ja) 2020-02-13
HUE058664T2 (hu) 2022-09-28
DK3558391T3 (da) 2022-05-09

Similar Documents

Publication Publication Date Title
CN110267685B (zh) 靶向adam9的免疫缀合物及其使用方法
TWI897855B (zh) Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
TWI831797B (zh) 靶向adam9之免疫接合物及其使用方法
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
KR20180130574A (ko) 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
US20250235548A1 (en) Antibody-drug conjugates targeting napi2b and methods of use
JP2025524628A (ja) Ｅｐｃａｍイムノコンジュゲート及びその使用
EP3402465A1 (en) Formulation for antibody and drug conjugate thereof
TW202430557A (zh) Ａｎｔｉ－Ｍｅｔ抗體、抗體藥物偶聯物及其製備方法和用途
WO2024077170A1 (en) Anti-urokinase-type plasminogen activator receptor antibodies and methods of use
JP2025516775A (ja) 新規なマスクされた抗体
HK40015128B (en) Immunoconjugates targeting adam9 and methods of use thereof
HK40015128A (en) Immunoconjugates targeting adam9 and methods of use thereof
TW202602943A (zh) 抗ｔｒｏｐ２抗體藥物偶聯物及使用方法
JP2025531990A (ja) ｃ－Ｍｅｔを標的とする抗体薬物コンジュゲート及び使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant